Rovast Special Precautions

Rosuvastatin should be used with caution in patients who have a history of liver disease and/or consume substantial quantities of alcohol. Statins should not be used in patients who already have unexplained persistently raised serum-aminotransferase concentrations and should be stopped if marked or persistent increases in serum-aminotransferase concentrations occur.
Rosuvastatin should be prescribed with caution in patients with predisposing factors for myopathy, such as, renal impairment, advanced age and inadequately treated hyperthyroidism.
Rosuvastatin, being an HMG-CoA reductase inhibitor, effects on skeletal muscle are uncomplicated myalgia and myopathy. Patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Rosuvastatin therapy should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected.
The risk of myopathy during treatment with rosuvastatin may be increased with concurrent administration of other lipid lowering therapies, ciclosporin, or lopinavir/ritonavir.
Rosuvastatin therapy should also be temporarily withheld in any patient with an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, dehydration, major surgery, trauma, severe metabolic endocrine, and electrolyte disorders, or uncontrolled seizures).
Combination therapy of rosuvastatin and gemfibrozil should generally be avoided.